BCG Vaccine Shows Promise Against Dementia in Mice

Johns Hopkins researchers find that the vaccine may reduce key dementia indicators by enhancing the immune system.

Updated on Oct. 21, 2026 in Alzheimer’s

BCG Vaccine Shows Promise Against Dementia in Mice

Live Poll

Do you believe existing vaccines should be prioritized for their potential off-target health benefits?

Researchers at the Johns Hopkins University School of Medicine discovered that the BCG vaccine helps clear harmful brain proteins in mice. The treatment, which uses an altered strain of Mycobacterium bovis, successfully normalized gene expression linked to Alzheimer's disease.

Why it matters

The study suggests that BCG-induced trained immunity can help innate immune cells identify and clear brain plaques. This mechanism may provide a new therapeutic pathway to address tau protein accumulation, which is a hallmark of dementia progression.

BCG-treated mice showed five times the reduction in tau deposits and four times lower sustained inflammation compared to untreated controls. Out of 716 Alzheimer's-associated genes activated in the disease model, only nine remained abnormal after vaccination.

The players

Johns Hopkins University School of Medicine

This is a world-renowned medical research and teaching institution based in Baltimore that frequently leads clinical and preclinical studies.

The details

By reprogramming myeloid cells through metabolomic and epigenetic changes, the BCG vaccine enables the immune system to actively target and clear tau neurofibrillary tangles. Mice receiving the vaccine at three months old demonstrated improved survival rates and body weight maintenance compared to the control group.

Mice received the BCG vaccine at three months of age.
Assessments of brain health occurred eight to nine months after vaccination.
Human observational studies linking BCG usage to dementia risk spanned three to 15 years.

The Big Picture

This study advances the ongoing investigation into BCG-induced trained immunity by providing a genetic mechanism for symptom reduction in a mouse model. The findings extend existing knowledge by linking this immunological process to the clearance of Alzheimer's-related brain proteins.

This preclinical discovery offers a potential new direction for future dementia therapies, though it does not change current standard medical care or treatment protocols. Patients should continue to rely on established clinical guidelines while research into immune-based interventions evolves.

The takeaway

While the results in mice are encouraging, the vaccine is currently in the preclinical stage for this specific application. Researchers are now looking toward human trials to see if these immunological benefits can effectively slow cognitive decline in patients.

What happens next

Researchers are planning to conduct large-scale prospective clinical trials in humans to determine if the results observed in mice translate to clinical dementia treatment.